These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 23838916)

  • 41. Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria.
    Aichler M; Elsner M; Ludyga N; Feuchtinger A; Zangen V; Maier SK; Balluff B; Schöne C; Hierber L; Braselmann H; Meding S; Rauser S; Zischka H; Aubele M; Schmitt M; Feith M; Hauck SM; Ueffing M; Langer R; Kuster B; Zitzelsberger H; Höfler H; Walch AK
    J Pathol; 2013 Aug; 230(4):410-9. PubMed ID: 23592244
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Insulin-like growth factor receptor 1 mRNA expression as a prognostic marker in advanced non-small cell lung cancer.
    Vilmar A; Santoni-Rugiu E; Cillas JG; Huarriz M; Sørensen JB
    Anticancer Res; 2014 Jun; 34(6):2991-6. PubMed ID: 24922664
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aldehyde dehydrogenase 1 expression is associated with poor prognosis in patients with esophageal squamous cell carcinoma.
    Minato T; Yamamoto Y; Seike J; Yoshida T; Yamai H; Takechi H; Yuasa Y; Furukita Y; Goto M; Bando Y; Tangoku A
    Ann Surg Oncol; 2013 Jan; 20(1):209-17. PubMed ID: 22847125
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China.
    Song B; Cui H; Li Y; Cheng C; Yang B; Wang F; Kong P; Li H; Zhang L; Jia Z; Bi Y; Wang J; Zhou Y; Liu J; Wang J; Zhao Z; Zhang Y; Hu X; Shi R; Yang J; Liu H; Yan T; Li Y; Xu E; Qian Y; Xi Y; Guo S; Chen Y; Wang J; Li G; Liang J; Jia J; Chen X; Guo J; Wang T; Zhang Y; Li Q; Wang C; Cheng X; Zhan Q; Cui Y
    Oncotarget; 2016 Jan; 7(3):3599-613. PubMed ID: 26528858
    [TBL] [Abstract][Full Text] [Related]  

  • 45. REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy.
    Sato Y; Motoyama S; Nanjo H; Ito S; Yoshino K; Sasaki T; Kuribayashi K; Nagaki Y; Imai K; Saito H; Minamiya Y; Ogawa J
    Ann Surg Oncol; 2013 Sep; 20(9):3044-51. PubMed ID: 23645481
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum microRNA profiles as prognostic/predictive markers in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction.
    Odenthal M; Hee J; Gockel I; Sisic L; Schmitz J; Stoecklein NH; Driemel C; Möhlendick B; Schmidt T; Knoefel WT; Lang H; Büttner R; Ott K; Vallböhmer D
    Int J Cancer; 2015 Jul; 137(1):230-7. PubMed ID: 25429911
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?
    Chiu CH; Chao YK; Chang HK; Tseng CK; Chan SC; Liu YH; Chen WH
    Ann Surg Oncol; 2013 Dec; 20(13):4245-51. PubMed ID: 23959050
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone.
    Ancona E; Ruol A; Santi S; Merigliano S; Sileni VC; Koussis H; Zaninotto G; Bonavina L; Peracchia A
    Cancer; 2001 Jun; 91(11):2165-74. PubMed ID: 11391598
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prediction of the response to chemotherapy in advanced esophageal cancer by gene expression profiling of biopsy samples.
    Motoori M; Takemasa I; Yamasaki M; Komori T; Takeno A; Miyata H; Takiguchi S; Fujiwara Y; Yasuda T; Yano M; Matsuura N; Matsubara K; Monden M; Mori M; Doki Y
    Int J Oncol; 2010 Nov; 37(5):1113-20. PubMed ID: 20878059
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Preoperative chemoradiation in esophageal cancer: experience of a single center in 102 patients].
    Imdahl A; Schöffel U; Ruf G; Hopf UT
    Zentralbl Chir; 2004 Oct; 129(5):350-5. PubMed ID: 15486784
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma.
    Kurashige J; Kamohara H; Watanabe M; Tanaka Y; Kinoshita K; Saito S; Hiyoshi Y; Iwatsuki M; Baba Y; Baba H
    J Surg Oncol; 2012 Aug; 106(2):188-92. PubMed ID: 22354855
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neoadjuvant chemotherapy (FAP) for advanced esophageal cancer.
    Shimakawa T; Naritaka Y; Asaka S; Isohata N; Murayama M; Konno S; Yoshimatsu K; Shiozawa S; Katsube T; Ogawa K
    Anticancer Res; 2008; 28(4C):2321-6. PubMed ID: 18751413
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).
    Noske A; Loibl S; Darb-Esfahani S; Roller M; Kronenwett R; Müller BM; Steffen J; von Toerne C; Wirtz R; Baumann I; Hoffmann G; Heinrich G; Grasshoff ST; Ulmer HU; Denkert C; von Minckwitz G
    Breast Cancer Res Treat; 2011 Feb; 126(1):109-17. PubMed ID: 21190079
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma.
    Langer R; Specht K; Becker K; Ewald P; Bekesch M; Sarbia M; Busch R; Feith M; Stein HJ; Siewert JR; Höfler H
    Clin Cancer Res; 2005 Oct; 11(20):7462-9. PubMed ID: 16243820
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma.
    Solomon N; Mezentsev D; Reis I; Lima M; Rios J; Avisar E; Franceschi D; Livingstone A; Podolsky L; Ardalan B
    Jpn J Clin Oncol; 2011 Apr; 41(4):469-76. PubMed ID: 21258083
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided?
    Cools-Lartigue J; Jones D; Spicer J; Zourikian T; Rousseau M; Eckert E; Alcindor T; Vanhuyse M; Asselah J; Ferri LE
    Ann Surg Oncol; 2015; 22(6):1858-65. PubMed ID: 25476030
    [TBL] [Abstract][Full Text] [Related]  

  • 58. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.
    Makino T; Yamasaki M; Miyata H; Yoshioka S; Takiguchi S; Fujiwara Y; Nakajima K; Nishida T; Mori M; Doki Y
    Ann Surg Oncol; 2010 Mar; 17(3):804-11. PubMed ID: 19885698
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
    Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
    Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    Kelsen DP; Ginsberg R; Pajak TF; Sheahan DG; Gunderson L; Mortimer J; Estes N; Haller DG; Ajani J; Kocha W; Minsky BD; Roth JA
    N Engl J Med; 1998 Dec; 339(27):1979-84. PubMed ID: 9869669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.